Inconformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the Company) hereby notifies the market of the following:
The Company's issued share capital as at 31 January 2013 consisted of 5,398,727,128 Ordinary Shares of 25p each, ofwhich494,951,327Ordinary Shares were held in Treasury.
Therefore, thetotal number of voting rights in the Company is 4,903,775,801. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Services Authority's Disclosure and Transparency Rules.
V A Whyte
1 February 2013
This information is provided by RNS
The company news service from the London Stock Exchange